Reviews
Review proposes decision framework for systemic melanoma therapy in heart failure
Serban et alJournal of Clinical Medicine
General cardio-oncology recommendations establish cardiovascular toxicity profiles for immune checkpoint inhibitors and targeted BRAF/MEK inhibitors, yet specific guidance remains limited regarding systemic melanoma management in patients with pre-existing heart failure. A critical narrative review addressing this clinical scenario identified that direct evidence for treating melanoma in the setting of established heart failure is currently confined to case-level reports, with broader cardiotoxicity estimates derived from selected longitudinal and real-world cohorts.
To bridge this gap, a procedural decision framework was developed across four core domains: heart failure phenotype and stability; oncological urgency and viable alternatives; treatment-specific toxicity phenotypes; and detectability, reversibility, and patient-centered priorities. The framework applies explicit precedence rules to resolve scenarios where multiple domains are abnormal, guiding modifications to symptom interpretation, cardiac biomarker surveillance, ventricular function assessments, drug-drug interaction management, and protocols for treatment interruption or rechallenge.
Importantly, the framework distinguishes heart failure with preserved ejection fraction as a distinct clinical phenotype in which functional decompensation may occur without a measurable reduction in left ventricular ejection fraction. It also highlights the necessity of explicitly documenting individualized priorities in older adults, such as quality of life, avoidance of hospitalization, route of administration, and functional expectations. The authors emphasize that while stable heart failure should not preclude potentially curative or life-prolonging systemic melanoma therapy, active decompensation mandates stabilization before treatment initiation or intensive monitoring when oncological intervention cannot be safely delayed.
Key Takeaways
- Stable pre-existing heart failure is not an automatic contraindication to effective systemic melanoma therapy, whereas active or recent decompensation requires clinical stabilization or closely monitored therapy when oncological delay poses imminent risk.
- In patients with heart failure with preserved ejection fraction receiving systemic melanoma regimens, clinical heart failure deterioration can manifest without any measurable change in left ventricular ejection fraction.
- Direct evidence evaluating systemic melanoma treatments such as BRAF/MEK inhibitors and immune checkpoint inhibitors in patients with established heart failure is restricted entirely to case-level reports.
Read the original sourceJournal of Clinical Medicine
